Daniel B Larremore

InstitutionSanta Fe Institute
AddressSanta Fe
New Mexico
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 11 Covid-19 publications, with a maximum of 3 publications in March 2021
    All Publications
    Bar chart showing 26 publications over 9 distinct years, with a maximum of 9 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bjorkman KK, Saldi TK, Lasda E, Bauer LC, Kovarik J, Gonzales PK, Fink MR, Tat KL, Hager CR, Davis JC, Ozeroff CD, Brisson GR, Larremore DB, Leinwand LA, McQueen MB, Parker R. Higher Viral Load Drives Infrequent Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Between Asymptomatic Residence Hall Roommates. J Infect Dis. 2021 10 28; 224(8):1316-1324. PMID: 34302469.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    2. Larremore DB, Toomre D, Parker R. Modeling the effectiveness of olfactory testing to limit SARS-CoV-2 transmission. Nat Commun. 2021 06 16; 12(1):3664. PMID: 34135322.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    3. Larremore DB, Bubar KM, Grad YH. Implications of Test Characteristics and Population Seroprevalence on "Immune Passport" Strategies. Clin Infect Dis. 2021 05 04; 72(9):e412-e414. PMID: 32687149.
      Citations: 3     Fields:    Translation:Humans
    4. Cobey S, Larremore DB, Grad YH, Lipsitch M. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol. 2021 05; 21(5):330-335. PMID: 33795856.
      Citations: 21     Fields:    Translation:HumansPHPublic Health
    5. Nisar MI, Ansari N, Khalid F, Amin M, Shahbaz H, Hotwani A, Rehman N, Pugh S, Mehmood U, Rizvi A, Memon A, Ahmed Z, Ahmed A, Iqbal J, Saleem AF, Aamir UB, Larremore DB, Fosdick B, Jehan F. Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan. Int J Infect Dis. 2021 May; 106:176-182. PMID: 33737137.
      Citations: 4     Fields:    Translation:Humans
    6. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, Buckee CO, Grad YH. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. Elife. 2021 03 05; 10. PMID: 33666169.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    7. Sabourin KR, Schultz J, Romero J, Lamb MM, Larremore D, Morrison TE, Frazer-Abel A, Zimmer S, Kedl RM, Jaenisch T, Rochford R. Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders-The COVID-19 Arapahoe SErosurveillance Study (CASES) Project. J Occup Environ Med. 2021 03 01; 63(3):191-198. PMID: 33298759.
      Citations: 1     Fields:    Translation:Humans
    8. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, Larremore DB. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 02 26; 371(6532):916-921. PMID: 33479118.
      Citations: 112     Fields:    Translation:HumansPHPublic Health
    9. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. 2021 01; 7(1). PMID: 33219112.
      Citations: 201     Fields:    Translation:HumansPHPublic Health
    10. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med. 2020 Nov 26; 383(22):e120. PMID: 32997903.
      Citations: 174     Fields:    Translation:HumansPHPublic Health
    11. Kissler SM, Kishore N, Prabhu M, Goffman D, Beilin Y, Landau R, Gyamfi-Bannerman C, Bateman BT, Snyder J, Razavi AS, Katz D, Gal J, Bianco A, Stone J, Larremore D, Buckee CO, Grad YH. Reductions in commuting mobility correlate with geographic differences in SARS-CoV-2 prevalence in New York City. Nat Commun. 2020 09 16; 11(1):4674. PMID: 32938924.
      Citations: 34     Fields:    Translation:HumansCellsPHPublic Health
    Larremore's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (79)
    Explore
    _
    Co-Authors (73)
    Explore
    _
    Similar People (60)
    Explore
    _